Author

Walter Reinisch

ASSOCIATION OF HISTOLOGIC MEASUREMENT WITH ENDOSCOPIC OUTCOMES AFTER ONE YEAR OF TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE
ASSOCIATION OF HISTOLOGIC MEASUREMENT WITH ENDOSCOPIC OUTCOMES AFTER ONE YEAR OF TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE

Walter Reinisch  et al.

POSTOPERATIVE IMMUNOSUPPRESSIVE THERAPY DOES NOT INFLUENCE ENDOSCOPIC RECURRENCE RATES AFTER BOWEL RESECTIONS DUE TO CROHN’S DISEASE – A RETROSPECTIVE MULTICENTRE ANALYSIS
POSTOPERATIVE IMMUNOSUPPRESSIVE THERAPY DOES NOT INFLUENCE ENDOSCOPIC RECURRENCE RATES AFTER BOWEL RESECTIONS DUE TO CROHN’S DISEASE – A RETROSPECTIVE MULTICENTRE ANALYSIS

Walter Reinisch  et al.

SERUM LIPID AND C-REACTIVE PROTEIN LEVELS BY TREATMENT RESPONSE FOLLOWING 8 WEEKS OF TOFACITINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
SERUM LIPID AND C-REACTIVE PROTEIN LEVELS BY TREATMENT RESPONSE FOLLOWING 8 WEEKS OF TOFACITINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

Walter Reinisch  et al.

IMPACT OF COVID-19 ON PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM AN INTERNATIONAL REGISTRY
IMPACT OF COVID-19 ON PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM AN INTERNATIONAL REGISTRY

Walter Reinisch  et al.

LONG-TERM EFFECTIVENESS OF DARVADSTROCEL IN PATIENTS WITH COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE: RESULTS FROM INSPECT, A RETROSPECTIVE CHART REVIEW STUDY IN EUROPE
LONG-TERM EFFECTIVENESS OF DARVADSTROCEL IN PATIENTS WITH COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE: RESULTS FROM INSPECT, A RETROSPECTIVE CHART REVIEW STUDY IN EUROPE

Walter Reinisch  et al.

TREATMENT DISCONTINUATION DUE TO LACK OF EFFICACY DURING MAINTENANCE TREATMENT WITH INFLIXIMAB OR VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE: A COMPARATIVE ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
TREATMENT DISCONTINUATION DUE TO LACK OF EFFICACY DURING MAINTENANCE TREATMENT WITH INFLIXIMAB OR VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE: A COMPARATIVE ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Walter Reinisch  et al.

PREVALENCE OF SURGERY IN PATIENTS WITH CROHN’S DISEASE IN AUSTRIA – A NATIONWIDE RETROSPECTIVE STUDY FROM 2011 THROUGH 2019
PREVALENCE OF SURGERY IN PATIENTS WITH CROHN’S DISEASE IN AUSTRIA – A NATIONWIDE RETROSPECTIVE STUDY FROM 2011 THROUGH 2019

Walter Reinisch  et al.

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL

Walter Reinisch  et al.

RADIOLOGIC EVALUATION OF FILGOTINIB TREATMENT IN PERIANAL FISTULIZING CROHN’S DISEASE USING A NOVEL SCORING SYSTEM
RADIOLOGIC EVALUATION OF FILGOTINIB TREATMENT IN PERIANAL FISTULIZING CROHN’S DISEASE USING A NOVEL SCORING SYSTEM

Walter Reinisch  et al.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATED ANALYSIS OF INFECTION RATES IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATED ANALYSIS OF INFECTION RATES IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME

Walter Reinisch  et al.

A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Walter Reinisch  et al.

MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: FINAL RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN
MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: FINAL RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN

Walter Reinisch  et al.

MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME
MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME

Walter Reinisch  et al.

EXPOSURE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) IN PATIENTS WITH ACTIVE CROHN'S DISEASE AND ULCERATIVE COLITIS: ANALYSIS FROM A MULTICENTER, RANDOMIZED CONTROLLED PIVOTAL TRIAL
EXPOSURE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) IN PATIENTS WITH ACTIVE CROHN'S DISEASE AND ULCERATIVE COLITIS: ANALYSIS FROM A MULTICENTER, RANDOMIZED CONTROLLED PIVOTAL TRIAL

Walter Reinisch  et al.

THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 INTERIM ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY
THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 INTERIM ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY

Walter Reinisch  et al.

COBITOLIMOD FOR MODERATE-TO-SEVERE LEFT-SIDED ULCERATIVE COLITIS (CONDUCT): A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL
COBITOLIMOD FOR MODERATE-TO-SEVERE LEFT-SIDED ULCERATIVE COLITIS (CONDUCT): A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL

Walter Reinisch  et al.

HEALTH-RELATED QUALITY OF LIFE WITH GUSELKUMAB INDUCTION AND MAINTENANCE THERAPY AS MEASURED BY PROMIS-29: RESULTS THROUGH WEEK 48 OF PHASE 2 GALAXI 1 STUDY
HEALTH-RELATED QUALITY OF LIFE WITH GUSELKUMAB INDUCTION AND MAINTENANCE THERAPY AS MEASURED BY PROMIS-29: RESULTS THROUGH WEEK 48 OF PHASE 2 GALAXI 1 STUDY

Walter Reinisch  et al.

Item 41 - 57 / 57
1 2
3